MedPath

Evaluation of Indocyanine Green dye for sentinel lymph node biopsy in breast cancer

Not Applicable
Conditions
Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: C509- Malignant neoplasm of breast of unspecified site
Registration Number
CTRI/2022/09/045719
Lead Sponsor
Department of Surgical Disciplines
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Upfront operable primary breast cancer measuring upto and including 5cm in maximum tumour dimension with clinically lymph node negative breast cancers (Tis, T1,T2-N0) undergoing upfront surgery

Consenting patient

Exclusion Criteria

Pregnant or lactating women

Patients who have received neo-adjuvant chemotherapy.

Patients with history of previous surgery of axilla or chest wall.

Patients with history of previous radiotherapy to the breast or axilla.

H/o hypersensitivity to any of the agents used.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
identification and comparison of sentinel lypmh node proportions using Indocyanine green with the standard radio colloid- methylene blue dye method.Timepoint: Baseline
Secondary Outcome Measures
NameTimeMethod
Procedure time of doing sentinel lymph node biopsy from time of skin incision to identification of sentinel lymph node in each group.Timepoint: Baseline
© Copyright 2025. All Rights Reserved by MedPath